-transparent.png){kind=logo}
The actions of misonidazole as a radiation sensitizer, hypoxic cytotoxic, and metabolic inhibitor are all concentration-dependent, and the commonly prescribed oral dose (12 g/m2) appears to be inadequate. The drug has, therefore, been given interstitially in solid form, when local tissue doses of the order of tens of millimolar are attained, to four patients, all with advanced disease. In the three cases (two squamous carcinomas and a malignant melanoma) in whom the drug concentration was considered to be adequate, a beneficial effect was obtained, which, in two instances, was associated with doses of radiation of 6 and 8 Gy, respectively. This approach has a wide potential application in cancer therapy.
R Sealy, and
J Korrubel, and
S Cridland, and
G Blekkenhorst
April 1978,
The British journal of radiology,
R Sealy, and
J Korrubel, and
S Cridland, and
G Blekkenhorst
May 1983,
Gan no rinsho. Japan journal of cancer clinics,
R Sealy, and
J Korrubel, and
S Cridland, and
G Blekkenhorst
June 1984,
Gan to kagaku ryoho. Cancer & chemotherapy,
R Sealy, and
J Korrubel, and
S Cridland, and
G Blekkenhorst
December 2000,
Journal of experimental & clinical cancer research : CR,
R Sealy, and
J Korrubel, and
S Cridland, and
G Blekkenhorst
January 1979,
Cancer treatment reports,
R Sealy, and
J Korrubel, and
S Cridland, and
G Blekkenhorst
February 1986,
Nihon Gan Chiryo Gakkai shi,
R Sealy, and
J Korrubel, and
S Cridland, and
G Blekkenhorst
January 1985,
Journal of cancer research and clinical oncology,
R Sealy, and
J Korrubel, and
S Cridland, and
G Blekkenhorst
January 1980,
Cancer clinical trials,
R Sealy, and
J Korrubel, and
S Cridland, and
G Blekkenhorst
August 1985,
Cancer,
R Sealy, and
J Korrubel, and
S Cridland, and
G Blekkenhorst
September 1980,
Indian journal of cancer,
